Tsirigotis P, et al. - Given that treatment with brentuximab vedotin (BV; an anti-CD30 monoclonal antibody-drug conjugate) had an overall response rate of 75% and a median progression-free survival of 6.7 months in a key phase II study, researchers assessed the effect of BV on overall survival (OS) in a post autologous stem cell transplantation (auto-SCT) for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) setting. A multivariate model was used and patients were censored at the time of subsequent allo-SCT or treatment with immune checkpoint inhibitors. The use of BV in the posttransplant relapse setting has a positive impact on the outcome and significantly improved OS was attained. Researchers believed this is the first published study on the impact of BV on OS in the setting of posttransplant relapse.